David Procaccini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Procaccini has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
John D. Coulson
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2 shared publicationsSapna R. Kudchadkar
Departments of Anesthesiology and Critical Care Medicine, Pediatrics, and Physical Medicine & Rehabilitation (SK), The Johns Hopkins School of Medicine, Baltimore, Maryland
2 shared publicationsAbigail Self
Department of Anesthesiology & Critical Care Medicine (DD, AS), The Johns Hopkins Hospital, Baltimore, MD
1 shared publication- Ann Marie Ruhe
Department of Pharmacy, Sheppard Pratt, 6501 N. Charles Street, Baltimore, MD 21204, USA
1 shared publication Blair Anton
Welch Medical Library, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
1 shared publicationDawoon Jung
Center for Translational Medicine, School of Pharmacy University of Maryland Baltimore Maryland USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2025 (1)
Neutropenia Associated With Furosemide Administration in a Preterm Infant
Furosemide is a commonly used diuretic, though there is scant literature describing its association with leukopenia. We present a case of neutropenia observed in a preterm infant with a congenital heart anomaly, who received both oral and intravenous furosemide over the course of two hospitalizations. Using the Naranjo adverse drug reaction probability scale, we posit that furosemide was the probable cause of this observed hematologic trend; other etiologies of neutropenia, such as infection, allergy, or physiologic nadir, are unlikely to explain the neutropenia observed in our patient.
- 1 January 2025
- Published by Wiley in Case Reports in Pediatrics
- Vol. 2025 (1)
Open AccessNeutropenia Associated With Furosemide Administration in a Preterm Infant
Furosemide is a commonly used diuretic, though there is scant literature describing its association with leukopenia. We present a case of neutropenia observed in a preterm infant with a congenital heart anomaly, who received both oral and intravenous furosemide over the course of two hospitalizations. Using the Naranjo adverse drug reaction probability scale, we posit that furosemide was the probable cause of this observed hematologic trend; other etiologies of neutropenia, such as infection, allergy, or physiologic nadir, are unlikely to explain the neutropenia observed in our patient.
- 20 March 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (8) , 2396-2406
Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation
Aims: There remains a paucity of literature regarding best practice for antithrombin (AT) monitoring, dosing and dose–response in paediatric extracorporeal membrane oxygenation (ECMO) patients.Methods: We conducted a retrospective cohort study at a quaternary care paediatric intensive care unit in all patients vs. pre‐AT replacement were compared in order to characterize a dose–response relationship.Results: The final cohort included 191 patients with 201 ECMO runs and 2028 AT activity measurements. The median AT activity was 65% (interquartile range [IQR], 51–82) and 879 (43.3%) measurements met the criteria of deficient. The overall median AT dose and increase in AT activity were 50.6 units/kg/dose (IQR, 39.5–67.2) and 23.5% (IQR, 9.8–36.0), respectively. In the protocol that restricted AT activity measurements to clinical scenarios concerning for heparin resistance, there was significantly higher dosing in conjunction with significantly fewer overall administrations. Approximately one third of AT activity remained deficient after repletion. There was no difference in mechanical complications, reasons for discontinuation of ECMO support, time on ECMO or survival between protocols.Conclusions: There was a high prevalence of AT deficiency in paediatric ECMO patients. An AT replacement protocol based on evaluating heparin resistance is associated with fewer AT administrations, with similar circuit and patient outcomes. Further data are needed to identify optimal dosing strategies.
- 20 March 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (8) , 2396-2406
Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation
Aims: There remains a paucity of literature regarding best practice for antithrombin (AT) monitoring, dosing and dose–response in paediatric extracorporeal membrane oxygenation (ECMO) patients.Methods: We conducted a retrospective cohort study at a quaternary care paediatric intensive care unit in all patients vs. pre‐AT replacement were compared in order to characterize a dose–response relationship.Results: The final cohort included 191 patients with 201 ECMO runs and 2028 AT activity measurements. The median AT activity was 65% (interquartile range [IQR], 51–82) and 879 (43.3%) measurements met the criteria of deficient. The overall median AT dose and increase in AT activity were 50.6 units/kg/dose (IQR, 39.5–67.2) and 23.5% (IQR, 9.8–36.0), respectively. In the protocol that restricted AT activity measurements to clinical scenarios concerning for heparin resistance, there was significantly higher dosing in conjunction with significantly fewer overall administrations. Approximately one third of AT activity remained deficient after repletion. There was no difference in mechanical complications, reasons for discontinuation of ECMO support, time on ECMO or survival between protocols.Conclusions: There was a high prevalence of AT deficiency in paediatric ECMO patients. An AT replacement protocol based on evaluating heparin resistance is associated with fewer AT administrations, with similar circuit and patient outcomes. Further data are needed to identify optimal dosing strategies.
- 1 January 2023
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 28 (1) , 102-107
Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient
We report a case of a 7-year old male with idiopathic pulmonary arterial hypertension, successfully transitioned from an intravenous infusion to inhaled treprostinil during inpatient admission, after his intentional removal of multiple central venous catheters. He had no clinical, echocardiographic, or serum biomarker evidence of loss of control of pulmonary arterial hypertension during the 4-day transition. The patient was discharged home without complications, and 3 weeks after discharge the patient's pulmonary hypertension remained well controlled per clinical and echocardiographic evidence, including a significantly improved 6-minute walk distance test.
- 1 January 2023
- Published by The Pediatric Pharmacy Association in The Journal of Pediatric Pharmacology and Therapeutics
- Vol. 28 (1) , 102-107
Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient
We report a case of a 7-year old male with idiopathic pulmonary arterial hypertension, successfully transitioned from an intravenous infusion to inhaled treprostinil during inpatient admission, after his intentional removal of multiple central venous catheters. He had no clinical, echocardiographic, or serum biomarker evidence of loss of control of pulmonary arterial hypertension during the 4-day transition. The patient was discharged home without complications, and 3 weeks after discharge the patient's pulmonary hypertension remained well controlled per clinical and echocardiographic evidence, including a significantly improved 6-minute walk distance test.
- 1 March 2022
- Published by Elsevier in The Joint Commission Journal on Quality and Patient Safety
- Vol. 48 (3) , 154-164
Medication Errors in Overweight and Obese Pediatric Patients: A Narrative Review
- 1 March 2022
- Published by Elsevier in The Joint Commission Journal on Quality and Patient Safety
- Vol. 48 (3) , 154-164
Medication Errors in Overweight and Obese Pediatric Patients: A Narrative Review
- 1 November 2021
- Published by American Academy of Pediatrics (AAP) in Hospital Pediatrics
- Vol. 11 (11) , e308-e312
Melatonin Administration Patterns for Pediatric Inpatients in a Tertiary Children’s Hospital
OBJECTIVES Melatonin has been trialed with reported increasing use for sleep dysregulation and prevention of ICU delirium in critically ill adults; however, reports of use in hospitalized pediatric patients are limited. We anecdotally observed an increase in prescribing of melatonin in our tertiary care children’s hospital and therefore aimed to retrospectively characterize prescribing practices over time. METHODS Melatonin dispensing data over a 4-year time frame were extracted. Melatonin doses were categorized as being either ICU or non-ICU administered and dosed during daytime versus nighttime, respectively. Descriptive statistics were used to characterize patients who were administered melatonin, dosing information, and quantitative change in annual melatonin orders between areas. The comparison of daytime versus nighttime melatonin administrations and ratio of administrations between ICU and non-ICU areas for each study year were compared via χ2 test. RESULTS Administration of melatonin increased 246.2% between years 1 and 3, with a shift from predominance in ICU to non-ICU areas over the study period (P < .0001). The average dosing varied by age, with the most frequent dose being 5 mg (28.3%), predominantly in patients ≥12 years of age. Ninety-eight percent (n = 9434) of doses were scheduled for nighttime administration, suggesting an indication of sleep regulation. There were significantly more daytime administrations of melatonin in non-ICU areas (P < .0001). CONCLUSIONS Prescribing of melatonin for pediatric inpatients has increased substantially over a 4-year period, despite limited research on dosing, in this single-center. Further research is needed to determine best practices for melatonin prescribing for hospitalized children.
- 1 November 2021
- Published by American Academy of Pediatrics (AAP) in Hospital Pediatrics
- Vol. 11 (11) , e308-e312
Melatonin Administration Patterns for Pediatric Inpatients in a Tertiary Children’s Hospital
OBJECTIVES Melatonin has been trialed with reported increasing use for sleep dysregulation and prevention of ICU delirium in critically ill adults; however, reports of use in hospitalized pediatric patients are limited. We anecdotally observed an increase in prescribing of melatonin in our tertiary care children’s hospital and therefore aimed to retrospectively characterize prescribing practices over time. METHODS Melatonin dispensing data over a 4-year time frame were extracted. Melatonin doses were categorized as being either ICU or non-ICU administered and dosed during daytime versus nighttime, respectively. Descriptive statistics were used to characterize patients who were administered melatonin, dosing information, and quantitative change in annual melatonin orders between areas. The comparison of daytime versus nighttime melatonin administrations and ratio of administrations between ICU and non-ICU areas for each study year were compared via χ2 test. RESULTS Administration of melatonin increased 246.2% between years 1 and 3, with a shift from predominance in ICU to non-ICU areas over the study period (P < .0001). The average dosing varied by age, with the most frequent dose being 5 mg (28.3%), predominantly in patients ≥12 years of age. Ninety-eight percent (n = 9434) of doses were scheduled for nighttime administration, suggesting an indication of sleep regulation. There were significantly more daytime administrations of melatonin in non-ICU areas (P < .0001). CONCLUSIONS Prescribing of melatonin for pediatric inpatients has increased substantially over a 4-year period, despite limited research on dosing, in this single-center. Further research is needed to determine best practices for melatonin prescribing for hospitalized children.
- 24 June 2021
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 56 (3) , 368-369
Continuous Opioid Infusions in Critically Ill Children
- 24 June 2021
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 56 (3) , 368-369
Continuous Opioid Infusions in Critically Ill Children
- 16 September 2020
- Published by Wiley in Anaesthesia
- Vol. 76 (6) , 837-849
Melatonin for anaesthetic indications in paediatric patients: a systematic review
Summary: The favourable safety profile and ubiquitous nature of melatonin has led to an increase in its use in various clinical settings in adults and children. We performed a systematic review of published studies on the use of melatonin for anaesthetic indications in paediatric patients. To identify relevant articles, PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature, Web of Science and Scopus databases were searched. Study title and abstract screening, and full text review were performed by two reviewers. Twenty‐seven eligible studies investigating melatonin use for anaesthetic indications were identified. Due to significant heterogeneity in study methodology, a quantitative synthesis of the published findings was not possible. The identified studies were therefore categorised by the indication for melatonin: analgesia, diagnostic sedation and as an anaesthetic adjunct. Melatonin use for anaesthetic‐related indications is safe; may provide analgesia for inflammatory‐associated pain in neonates and children before venepuncture; may decrease the need for, or replace, general anaesthesia for diagnostic procedures; and may serve as an anaesthesia adjunct before induction in paediatric patients.
- 16 September 2020
- Published by Wiley in Anaesthesia
- Vol. 76 (6) , 837-849
Melatonin for anaesthetic indications in paediatric patients: a systematic review
Summary: The favourable safety profile and ubiquitous nature of melatonin has led to an increase in its use in various clinical settings in adults and children. We performed a systematic review of published studies on the use of melatonin for anaesthetic indications in paediatric patients. To identify relevant articles, PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature, Web of Science and Scopus databases were searched. Study title and abstract screening, and full text review were performed by two reviewers. Twenty‐seven eligible studies investigating melatonin use for anaesthetic indications were identified. Due to significant heterogeneity in study methodology, a quantitative synthesis of the published findings was not possible. The identified studies were therefore categorised by the indication for melatonin: analgesia, diagnostic sedation and as an anaesthetic adjunct. Melatonin use for anaesthetic‐related indications is safe; may provide analgesia for inflammatory‐associated pain in neonates and children before venepuncture; may decrease the need for, or replace, general anaesthesia for diagnostic procedures; and may serve as an anaesthesia adjunct before induction in paediatric patients.
- 28 April 2020
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 40 (7) , 692-703
Melatonin Use in Hospitalized Children for Non‐Anesthetic Indications: A Systematic Review
Melatonin, a potent free radical scavenger, plays an important role in homeostasis of cell and organ physiology. The increased demand and synthesis from the pineal gland during times of oxidative stress suggests a potential benefit of melatonin supplementation during hospitalization for acute illness. Yet, the paucity of clinical studies for non‐anesthetic–associated indications in pediatric populations hampers the safe, effective, and consistent use of melatonin. The objective of this study was to systematically review published studies of melatonin use for non‐sedative and non‐analgesic indications in hospitalized pediatric patients. We conducted a search of PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, and Scopus databases for articles on the use of melatonin for pediatric patients in a hospital setting. Thirteen eligible studies, all in neonates, were identified. Data elements extracted included study design, number of study subjects, indication for melatonin therapy, and melatonin regimen (formulation, dosage, and duration). Because study methodologies were very heterogeneous, a quantitative synthesis of the published findings was not possible. The identified studies were therefore categorized by the indication of melatonin (adjuvant‐antioxidant or anti‐inflammatory therapy) in the following specific disease states: (i) acute infections, (ii) respiratory distress syndrome, (iii) neurologic injury, and (iv) jaundice. The current data suggest that melatonin is safe for use in hospitalized neonates. Melatonin may be beneficial for reducing inflammatory markers in neonatal patients with disease states and clinical sequelae that are associated with increased inflammation and oxidative stress. Melatonin, in conjunction with phototherapy, is not superior to use of vitamin D with phototherapy for treatment of neonatal jaundice. However, studies in other pediatric populations are needed given widespread use across clinical inpatient settings.
- 28 April 2020
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 40 (7) , 692-703
Melatonin Use in Hospitalized Children for Non‐Anesthetic Indications: A Systematic Review
Melatonin, a potent free radical scavenger, plays an important role in homeostasis of cell and organ physiology. The increased demand and synthesis from the pineal gland during times of oxidative stress suggests a potential benefit of melatonin supplementation during hospitalization for acute illness. Yet, the paucity of clinical studies for non‐anesthetic–associated indications in pediatric populations hampers the safe, effective, and consistent use of melatonin. The objective of this study was to systematically review published studies of melatonin use for non‐sedative and non‐analgesic indications in hospitalized pediatric patients. We conducted a search of PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, and Scopus databases for articles on the use of melatonin for pediatric patients in a hospital setting. Thirteen eligible studies, all in neonates, were identified. Data elements extracted included study design, number of study subjects, indication for melatonin therapy, and melatonin regimen (formulation, dosage, and duration). Because study methodologies were very heterogeneous, a quantitative synthesis of the published findings was not possible. The identified studies were therefore categorized by the indication of melatonin (adjuvant‐antioxidant or anti‐inflammatory therapy) in the following specific disease states: (i) acute infections, (ii) respiratory distress syndrome, (iii) neurologic injury, and (iv) jaundice. The current data suggest that melatonin is safe for use in hospitalized neonates. Melatonin may be beneficial for reducing inflammatory markers in neonatal patients with disease states and clinical sequelae that are associated with increased inflammation and oxidative stress. Melatonin, in conjunction with phototherapy, is not superior to use of vitamin D with phototherapy for treatment of neonatal jaundice. However, studies in other pediatric populations are needed given widespread use across clinical inpatient settings.
- Open Access
- 1 November 2018
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 8 (6) , 313-316
Clozapine-induced myocarditis in an adolescent male with DiGeorge Syndrome
DiGeorge Syndrome (22q11.2 deletion syndrome) is a chromosomal disorder associated with both congenital heart malformations and schizophrenia, which is often treatment-resistant and may warrant treatment with clozapine. Clozapine-induced myocarditis (CIM) is a rare complication of clozapine therapy, with a reported incidence ranging from 0.015% to 3%. Fulminant CIM has a nonspecific presentation in both adult and pediatric populations and a mortality rate approaching 50%. Few cases of pediatric CIM have been documented in the literature. This report highlights a case of CIM in an adolescent male with DiGeorge Syndrome whose clinical course was characterized by a subtle, nonspecific presentation and resolution with supportive care.
- 1 November 2018
- Published by American Association of Psychiatric Pharmacists (AAPP) in Mental Health Clinician
- Vol. 8 (6) , 313-316
Open AccessClozapine-induced myocarditis in an adolescent male with DiGeorge Syndrome
DiGeorge Syndrome (22q11.2 deletion syndrome) is a chromosomal disorder associated with both congenital heart malformations and schizophrenia, which is often treatment-resistant and may warrant treatment with clozapine. Clozapine-induced myocarditis (CIM) is a rare complication of clozapine therapy, with a reported incidence ranging from 0.015% to 3%. Fulminant CIM has a nonspecific presentation in both adult and pediatric populations and a mortality rate approaching 50%. Few cases of pediatric CIM have been documented in the literature. This report highlights a case of CIM in an adolescent male with DiGeorge Syndrome whose clinical course was characterized by a subtle, nonspecific presentation and resolution with supportive care.